Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 2/20 | 0.41 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.35 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.35 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.30 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7554466 | 0.86 | SLC1A3 (0.45) | GRIK1GRIK2TP53SLC1A3SLC1A2 | |
| SCHEMBL17212018 | 0.85 | GRIK1 (0.46) | GRIK1GRIK2SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL21243680 | 0.82 | GRIK1 (0.47) | GRIK1GRIK2SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL21243670 | 0.82 | GRIK1 (0.47) | GRIK1GRIK2SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL7841776 | 0.82 | GRIK1 (0.34) | GRIK1GRIK2 | |
| SCHEMBL6805457 | 0.81 | TSHR (0.41) | GRIK1GRIK2SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL7989232 | 0.77 | CHRM1 (0.40) | GRIK1GRIK2SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL8847323 | 0.77 | GRIK1 (0.35) | GRIK1GRIK2SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL7718052 | 0.77 | CHRM1 (0.40) | GRIK1GRIK2SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL9860882 | 0.76 | GRIK1 (0.37) | GRIK1GRIK2SLC1A3SLC1A2SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1121118-A4 | FORMAMIDES AS THERAPEUTIC AGENTS | GLAXO GROUP LTD (GB) | 2002-09-11 | — | — | EP | disclosed |
| US-6329400-B1 | INHIBITION OR ANTAGONISM OF MATRIX METALLOPROTEASES, AND/OR TUMOR NECROSIS FACTOR-ALPHA; EXTRACELLULAR MATRIX DEGRADATION, INHIBITION OF SHEDDING OF CELL SURFACE PROTEIN ECTODOMAINS AND CD23 PROTEOLYSIS | GLAXO WELLCOME INC. | 2001-12-11 | — | — | US | disclosed |
| EP-1121118-A1 | FORMAMIDES AS THERAPEUTIC AGENTS | GLAXO GROUP LIMITED (GB) | 2001-08-08 | — | — | EP | disclosed |
| US-6172064-B1 | METALLOPROTEASE INHIBITOR; ANTIARTHRITIC AGENTS, ANTIDIABETIC AGENTS; ANTITUMOR AGENTS | GLAXO WELLCOME INC. | 2001-01-09 | — | — | US | disclosed |
| WO-2000012083-A1 | FORMAMIDES AS THERAPEUTIC AGENTS | GLAXO GROUP LIMITED (GB) | 2000-03-09 | — | — | WO | disclosed |
| WO-2000012082-A1 | FORMAMIDE COMPOUNDS AS THERAPEUTIC AGENTS | GLAXO GROUP LIMITED (GB) | 2000-03-09 | — | — | WO | disclosed |